GLP Watchdog

Hers vs Willow

Hers has an open FDA warning letter dated September 9, 2025. Willow has none. On compounded semaglutide injection, Hers costs $1,200 less a year at standing rates: $199 a month against $299 a month at Willow.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

Hers / Willow

Hers logo

Hers

6.8/10

Willow logo

Willow

7.3/10

FDA warning letters
None on record
Pharmacy
Lowest standing price
$199/moCompounded semaglutide injection
$299/moCompounded semaglutide injection
States
All 50 states
35 states
Checked
Prices captured Record checked September 2026
Prices captured Record checked September 2026
Visit Hers
Visit Willow

Neither Hers nor Willow pays us. Links to them earn nothing. Scores: Hers 6.8, Willow 7.3. How we are paid

What the record shows

  1. 01

    Hers has an open FDA warning letter dated September 9, 2025. Willow has none.

  2. 02

    Hers names three pharmacies. Willow names five pharmacies.

  3. 03

    On compounded semaglutide injection, Hers costs $1,200 less a year at standing rates: $199 a month against $299 a month at Willow.

  4. 04

    Only Hers lists a price for brand-name tirzepatide pen. Only Willow lists a price for compounded tirzepatide injection.

  5. 05

    Hers covers 15 states Willow does not.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

Hers

Willow

Compounded semaglutide injection

$199/moLower

$2,388 a year

$299/mo

$3,588 a year

Compounded tirzepatide injection
Not sold or not priced

$399/mo

$4,788 a year

Brand-name tirzepatide pen

$299/mo

medication only, membership extra; not compared

Not sold or not priced
Price includes
Medication
Medication, clinician visits, shipping
Billed separately
Clinician visits, coaching
Not stated
Cancel any time
Yes, stated
Yes, stated
Minimum term
None
None
Refunds
No refund guaranteed once the pharmacy has processed an order
Full refund if you cancel before the prescription is sent to the pharmacy; none once the medication is compounded

Read off each seller’s own pages. Hers: September 28, 2026. Willow: July 10, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for Hers

6.8/10
  • $1,200 a year less on compounded semaglutide injection
  • Sells brand-name tirzepatide pen, which Willow does not price
  • Lists 50 states against 35
  • Open FDA warning letter, September 9, 2025
  • Price leaves out clinician visits and coaching
Visit Hers

The case for Willow

7.3/10
  • No FDA warning letter on record
  • Sells compounded tirzepatide injection, which Hers does not price
  • Price includes clinician visits
Visit Willow

Scores

Hers 6.8 · Willow 7.3 out of 10. Six weighted parts.

Value25%

3.0A
vs
B
3.0

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

7.0A
vs
B
9.0

Accessibility10%

10.0A
vs
B
7.6

Support10%

3.0A
vs
B
7.0

The score is the same formula for every seller. Payment does not enter it. Method

Hers vs Willow: questions

Hers has an open FDA warning letter dated September 9, 2025. Willow has none. Letters are matched to a seller by company, domain and address, never by a similar name.
Hers names three pharmacies. Willow names five pharmacies. A 503A pharmacy compounds for named patients on a prescription; a 503B outsourcing facility is registered with FDA and inspected under federal manufacturing rules.
Hers, by $1,200 a year at standing rates. Hers: $199 a month, about $2,388 a year. Willow: $299 a month, about $3,588 a year.
Hers states you can cancel at any time; refunds: no refund guaranteed once the pharmacy has processed an order. Willow states you can cancel at any time; refunds: full refund if you cancel before the prescription is sent to the pharmacy; none once the medication is compounded.
Neither Hers nor Willow pays us. Links to them earn nothing. Scores: Hers 6.8, Willow 7.3.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks